WO2024220712A3 - Vaccine compositions - Google Patents

Vaccine compositions Download PDF

Info

Publication number
WO2024220712A3
WO2024220712A3 PCT/US2024/025270 US2024025270W WO2024220712A3 WO 2024220712 A3 WO2024220712 A3 WO 2024220712A3 US 2024025270 W US2024025270 W US 2024025270W WO 2024220712 A3 WO2024220712 A3 WO 2024220712A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
vaccine compositions
ionizable lipid
lnmps
nucleic acid
Prior art date
Application number
PCT/US2024/025270
Other languages
French (fr)
Other versions
WO2024220712A2 (en
Inventor
Emad ARAFA
Munir MOSAHEB
Siddharth Patel
Alaina HOWE
Dominick SALERNO
Original Assignee
Sail Biomedicines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sail Biomedicines, Inc. filed Critical Sail Biomedicines, Inc.
Publication of WO2024220712A2 publication Critical patent/WO2024220712A2/en
Publication of WO2024220712A3 publication Critical patent/WO2024220712A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed herein are nucleic acid vaccine compositions including one or more polynucleotides encoding one or more antigenic polypeptide, formulated within a lipid reconstructed natural messenger packs (LNMPs) comprising natural lipids and an ionizable lipid. The disclosure also includes a method for making a nucleic acid vaccine, comprising reconstituting a film comprising purified NMP lipids in the presence of an ionizable lipid to produce a LNMP comprising the ionizable lipid, and loading into the LNMPs with one or more polynucleotides encoding one or more antigenic polypeptides.
PCT/US2024/025270 2023-04-19 2024-04-18 Vaccine compositions WO2024220712A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202363460389P 2023-04-19 2023-04-19
US63/460,389 2023-04-19
US202363514497P 2023-07-19 2023-07-19
US63/514,497 2023-07-19
US202363520809P 2023-08-21 2023-08-21
US63/520,809 2023-08-21
US202363596901P 2023-11-07 2023-11-07
US63/596,901 2023-11-07

Publications (2)

Publication Number Publication Date
WO2024220712A2 WO2024220712A2 (en) 2024-10-24
WO2024220712A3 true WO2024220712A3 (en) 2024-11-28

Family

ID=91335084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/025270 WO2024220712A2 (en) 2023-04-19 2024-04-18 Vaccine compositions

Country Status (1)

Country Link
WO (1) WO2024220712A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041301A1 (en) * 2019-08-24 2021-03-04 Flagship Pioneering Innovations Vi, Llc Modification of plant messenger packs with charged lipids
US20230108894A1 (en) * 2020-01-28 2023-04-06 Moderna TX, Inc Coronavirus rna vaccines
WO2023069498A1 (en) * 2021-10-22 2023-04-27 Senda Biosciences, Inc. Mrna vaccine composition

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0542874A4 (en) 1990-07-25 1994-05-11 Syngene Inc Circular extension for generating multiple nucleic acid complements
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
AU683011B2 (en) 1992-01-13 1997-10-30 Duke University Enzymatic RNA molecules
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5785992A (en) 1994-09-30 1998-07-28 Inex Pharmaceuticals Corp. Compositions for the introduction of polyanionic materials into cells
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
DE10121252A1 (en) 2001-04-30 2002-11-07 Christos C Zouboulis Acne treatment
ES2340532T3 (en) 2001-06-05 2010-06-04 Curevac Gmbh MRNA WITH AN INCREASED G / C CONTENT THAT CODIFIES FOR A BACTERIAL ANTIGEN AND USING THE SAME.
JP5243789B2 (en) 2004-03-15 2013-07-24 シティ・オブ・ホープ Methods and compositions for specific inhibition of gene expression by double stranded RNA
WO2005120152A2 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
EP1922300A2 (en) 2005-02-14 2008-05-21 Sirna Therapeutics Inc. Cationic lipids and formulated molecular compositions containing them
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (en) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
JP5296328B2 (en) 2007-05-09 2013-09-25 独立行政法人理化学研究所 Single-stranded circular RNA and method for producing the same
WO2009003222A1 (en) 2007-06-29 2009-01-08 Commonwealth Scientific And Industrial Research Organisation Methods for degrading toxic compounds
DK3156414T3 (en) 2007-09-26 2020-03-09 Intrexon Corp SYNTHETIC 5'PRESE EXPRESSION VECTORS AND METHODS FOR INCREASING TRANSGENIC EXPRESSION
EP2610340B1 (en) 2007-12-11 2014-10-01 The Scripps Research Institute Compositions and methods related to mRNA translational enhancer elements
US8513207B2 (en) 2008-12-18 2013-08-20 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
WO2010084371A1 (en) 2009-01-26 2010-07-29 Mitoprod Novel circular interfering rna molecules
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
CA2769670C (en) 2009-07-31 2018-10-02 Ethris Gmbh Rna with a combination of unmodified and modified nucleotides for protein expression
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
RS66304B1 (en) 2010-10-01 2025-01-31 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
CN103906527B (en) 2011-06-08 2020-07-10 川斯勒佰尔公司 Lipid Nanoparticle Compositions and Methods for mRNA Delivery
KR102014061B1 (en) 2011-10-03 2019-08-28 모더나 세라퓨틱스, 인코포레이티드 Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20150000461A (en) 2011-10-27 2015-01-02 메사추세츠 인스티튜트 오브 테크놀로지 Amino acid derivatives functionalized on the n-terminal capable of forming drug incapsulating microspheres
JP2015501844A (en) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Modified nucleosides, nucleotides and nucleic acid compositions
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
CN108949772A (en) 2012-04-02 2018-12-07 现代泰克斯公司 For generating the modification polynucleotides of biological agent relevant to human diseases and protein
EP2858679B2 (en) 2012-06-08 2024-06-05 Translate Bio, Inc. Pulmonary delivery of mrna to non-lung target cells
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc HETEROLOGIST UNTRANSLATED REGIONS FOR MRNA
ES2882110T3 (en) 2013-03-14 2021-12-01 Translate Bio Inc Methods and Compositions for Delivering mRNA-Encoded Antibodies
EP3578652B1 (en) 2013-03-15 2023-07-12 ModernaTX, Inc. Ribonucleic acid purification
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
DK2972360T3 (en) 2013-03-15 2018-05-22 Translate Bio Inc SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS THROUGH MIXED FORMULATIONS
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
US9925277B2 (en) 2013-09-13 2018-03-27 Modernatx, Inc. Polynucleotide compositions containing amino acids
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3623361B1 (en) 2013-12-19 2021-08-18 Novartis AG Lipids and lipid compositions for the delivery of active agents
RU2717986C2 (en) 2013-12-30 2020-03-27 Куревак Аг Artificial molecules of nucleic acid
JP6584414B2 (en) 2013-12-30 2019-10-02 キュアバック アーゲー Artificial nucleic acid molecule
PT3981437T (en) 2014-04-23 2025-01-15 Modernatx Inc Nucleic acid vaccines
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US20170175129A1 (en) 2014-06-19 2017-06-22 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170136132A1 (en) 2014-06-19 2017-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
CN106795096B (en) 2014-06-25 2020-05-29 爱康泰生治疗公司 Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
JP2017523777A (en) 2014-07-17 2017-08-24 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Polynucleotide end modification
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
DK3297637T3 (en) 2015-05-21 2021-08-02 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
CA2987066A1 (en) 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
PL3310764T3 (en) 2015-06-19 2023-11-06 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
PL3313829T3 (en) 2015-06-29 2024-08-19 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
ES2937963T3 (en) 2015-07-21 2023-04-03 Modernatx Inc Infectious disease vaccines
LT3350157T (en) 2015-09-17 2022-02-25 Modernatx, Inc. COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC SUBSTANCES
HUE059127T2 (en) 2015-10-22 2022-10-28 Modernatx Inc Respiratory virus vaccines
SMT202300052T1 (en) 2015-10-28 2023-05-12 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017117528A1 (en) 2015-12-30 2017-07-06 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
KR102617874B1 (en) 2016-03-30 2023-12-22 인텔리아 테라퓨틱스, 인크. Lipid nanoparticle formulations for CRISPR/CAS components
US10457631B2 (en) 2016-04-06 2019-10-29 Ohio State Innovation Foundation Biodegradable amino-ester nanomaterials for nucleic acid delivery
CN109937253B (en) 2016-09-14 2023-06-30 摩登纳特斯有限公司 High-purity RNA composition and preparation method thereof
MX2019004913A (en) 2016-10-26 2019-09-16 Curevac Ag Lipid nanoparticle mrna vaccines.
US11141476B2 (en) 2016-12-23 2021-10-12 Curevac Ag MERS coronavirus vaccine
CA3057394A1 (en) 2017-04-14 2018-10-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
EP3661563A4 (en) 2017-07-31 2021-11-10 The Ohio State Innovation Foundation BIOMIMETIC NANOMATERIALS AND USES THEREOF
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN111212905A (en) 2017-08-18 2020-05-29 摩登纳特斯有限公司 RNA polymerase variants
WO2019089828A1 (en) 2017-10-31 2019-05-09 Acuitas Therapeutics, Inc. Lamellar lipid nanoparticles
EP3709987A4 (en) 2017-11-14 2021-08-25 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derived ester lipids and uses thereof
MA51155A (en) 2017-12-15 2020-10-21 Flagship Pioneering Innovations Vi Llc COMPOSITIONS CONSISTING OF CIRCULAR POLYRIBONUCLEOTIDES AND THEIR USES
IL319091A (en) 2018-06-06 2025-04-01 Massachusetts Inst Technology Circular rna for translation in eukaryotic cells
AU2019310448A1 (en) 2018-07-24 2021-03-11 Mayo Foundation For Medical Education And Research Circularized engineered rna and methods
IL317488A (en) 2018-10-02 2025-02-01 Intellia Therapeutics Inc Ionizable amine lipids
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
TW202504886A (en) 2018-12-05 2025-02-01 美商英特利亞醫療公司 Modified amine lipids
SI3908568T1 (en) 2019-01-11 2024-11-29 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
CN114127044A (en) 2019-04-25 2022-03-01 英特利亚治疗股份有限公司 Ionizable amine lipids and lipid nanoparticles
WO2021263124A2 (en) 2020-06-25 2021-12-30 The Board Of Trustees Of The Leland Stanford Junior University Genetic elements driving circular rna translation and methods of use
EP4314289A1 (en) 2021-03-26 2024-02-07 Flagship Pioneering Innovations VII, LLC Production of circular polyribonucleotides in a prokaryotic system
US20240263206A1 (en) 2021-03-26 2024-08-08 Flagship Pioneering Innovations Vii, Llc Compositions and methods for producing circular polyribonucleotides
EP4314281A1 (en) 2021-03-26 2024-02-07 Flagship Pioneering Innovations VII, LLC Production of circular polyribonucleotides in a eukaryotic system
CN115404240A (en) 2021-05-28 2022-11-29 上海环码生物医药有限公司 Constructs, methods for making circular RNA and uses thereof
IL308746A (en) 2021-06-10 2024-03-01 Orna Therapeutics Inc Circular rna compositions and methods
ES2994006T3 (en) 2021-09-17 2025-01-16 Flagship Pioneering Innovations Vi Llc Compositions and methods for producing circular polyribonucleotides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041301A1 (en) * 2019-08-24 2021-03-04 Flagship Pioneering Innovations Vi, Llc Modification of plant messenger packs with charged lipids
US20230108894A1 (en) * 2020-01-28 2023-04-06 Moderna TX, Inc Coronavirus rna vaccines
WO2023069498A1 (en) * 2021-10-22 2023-04-27 Senda Biosciences, Inc. Mrna vaccine composition

Also Published As

Publication number Publication date
WO2024220712A2 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
AR003125A1 (en) BACTERIAL ANTIGENS FOR THE DIAGNOSIS OF INFECTIONS WITH HELICOBACTER PYLORI, A DNA MOLECLE THAT CODES IT, A VECTOR, A HOST CELL, A PROCEDURE FOR PRODUCING THE POLIPEPTIDE, USE OF ELEPIPETICO, AND PROAPILY USE
MX2024007594A (en) THERAPEUTIC COMPOSITIONS OF mRNA
ATE466869T1 (en) METHOD FOR PRODUCING IMMUNOGENIC HLA-A2.1-BINDING PEPTIDES
ATE264911T1 (en) A UNIVERSAL IMMUNOMODULATORY CYTOKINE EXPRESSING CELL LINE IN WAITING. APPLICABLE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USES
AR007714A1 (en) A STABLE NON-AQUEOUS FORMULATION OF A PEPTIDE COMPOUND, AND A METHOD FOR PREPARING THE FORMULATION.
CA2660355A1 (en) Polynucleotide vaccine formulation against pathologies of the horse
DZ634A1 (en) Non-toxigenic vibrio cholera mutants.
ATE355826T1 (en) METHOD FOR ENCAPSULATING NUCLEIC ACIDS IN LIPID DOUBLE LAYERS
ES2139591T3 (en) ASIALOGLYC PROTEINS FROM HEPATITIS C VIRUS.
WO2001072277A3 (en) Immunotherapeutic methods and compositions
DE60036537D1 (en) COMPOSITIONS FOR GENETHERAPY OF DIABETES
BR0017136A (en) Hla-binding peptides and their uses.
WO2024220712A3 (en) Vaccine compositions
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
GB9814538D0 (en) Helicobacter pylori bacterioferritin
WO1994025596A3 (en) Immunogenic formulation of ospc antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
WO1994024291A3 (en) Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation
ES548421A0 (en) A PROCEDURE FOR OBTAINING A MONOCLO-NAL ANTIBODY
ZA985393B (en) Clostridium perfringens vaccine
JPS5223600A (en) Method for making growth single crystal of gallium nitride
JP2016082979A5 (en)
AU8158898A (en) Improved (enterobacteriaceae) fermentation strains
Flower Superluminous giants in Magellanic Cloud clusters
NO942707L (en) Synthetic peptides suitable for rubella infections vaccine
WO2021222633A3 (en) Methods for treating covid-19